Read + Share

Amedeo Smart

Independent Medical Education


Read + Share

Overton ET, Richmond G, Rizzardini G, Jaeger H, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet 2021;396:1994-2005.
PMID: 33308425


Free Medical Abstracts
Privacy Policy
Sponsors
Share
About

© Amedeo 1997-2016